Glypisome Therapeutics for the Treatment of Peripheral Vascular Disease
Life Sciences : Therapeutics
Available for licensing
- Aaron Baker, Ph.D. , Biomedical Engineering
- Anthony Monteforte , Biomedical Engineering
Peripheral arterial disease (PAD), characterized by narrowing of arteries of the lower extremity, affects about 30 million people worldwide and it is estimated to affect over 16% of the general population over 65 years of age. Severe PAD has serious clinical consequences for patients, including the formation of ulcers, muscle pain and cramping, and increased risk for limb amputation.
The most severe form of PAD is known as critical limb ischemia (a state where there is pain even without movement). For patients with critical limb ischemia, there is a 50% amputation rate after one year of time. Unfortunately, clinical trials that use growth factors to stimulate angiogenesis and restore blood flow have for the most part been unsuccessful. Surgical interventions have shown significant symptomatic improvement, but the associated morbidity and mortality precludes routine use.
Dr. Aaron Baker has developed a newly invented class of compounds, termed glypisomes, to overcome the limitations of growth factor therapies. Glypisomes improve the activity and delivery of growth factors that stimulate the formation of new blood vessels. New treatment methods consisting of combinations of injectable glypisomes and growth factors can help restore blood flow and reverse the effects of PAD and critical limb ischemia.
- Improves the receptor binding, delivery and activity of angiogenic growth factors.
- Less invasive, lower risk, and lower cost alternative to surgical procedures such as arterial bypass surgery and percutaneous intervention like stenting and endarectomy.
- Reduces the incidence of hospitalization.
- Can provide new treatment options for patients for whom existing treatments are no longer effective or available.
Can be used in combination with other medical interventions
Glypisome treatment seeks to help the approximately 8 million Americans and 27 million people globally who are affected by PAD. It boasts an estimated market potential between $4.9 billion and $9.8 billion.
Proof of concept
- 1 U.S. patent application filed